Revelation Biosciences Inc. Announces Preclinical Biomarker Data Supporting Activity of REVTx-300

Author's Avatar
Feb 07, 2023

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”) announced today statistically significant results in a validated preclinical model of acute and chronic kidney disease. This mechanistic biomarker data further supports the potential clinical utility of REVTx-300 previously announced on November+18%2C+2022.